Intraretinal Microvascular Abnormalities and Venous Beading Have Different Genetic Profiles in Caucasian Patients with Non-Proliferative Diabetic Retinopathy

Overview

Journal Vision (Basel)

Specialty Ophthalmology

Date 2023 Mar 28

PMID 36977298

Authors

Elizabeth Pearce

Sobha Sivaprasad

Suzanne Broadgate

Christine Kiire

Susan M Downes

Stephanie Halford

Victor Chong

Affiliations

Soon will be listed here.

Abstract

Diabetic Retinopathy (DR) is a leading cause of preventable visual impairment in the working age population. Despite the increasing prevalence of DR, there remain gaps in our understanding of its pathophysiology. This is a prospective case-control study comparing the genetic profiles of patients with no DR vs. non-proliferative DR (NPDR) focusing on intraretinal microvascular abnormalities (IRMA) and venous beading (VB) in Caucasians. A total of 596 participants were recruited to the study; 199 with moderate/severe NPDR and 397 with diabetes for at least 5 years without DR. Sixty-four patients were excluded due to technical issues. In total, 532 were analysed; 181 and 351 were in the NPDR group and no DR group, respectively. Those with severe IRMA and VB had distinctly different genetic profiles from each other and from the no DR group, which further supports the theory that these two features of DR might have different etiologies. This also suggests that IRMA and VB are independent risk factors for the development of PDR and may have different pathophysiologies. If these findings are confirmed in larger studies, this could pave the way for personalised treatment options for those more at risk of developing different features of NPDR.

References

. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):786-806. View

Ding H, Howarth A, Pannirselvam M, Anderson T, Severson D, Wiehler W . Endothelial dysfunction in Type 2 diabetes correlates with deregulated expression of the tail-anchored membrane protein SLMAP. Am J Physiol Heart Circ Physiol. 2005; 289(1):H206-11. DOI: 10.1152/ajpheart.00037.2005. View

Upadhyay R, Robay A, Fakhro K, Abi Khalil C, Zirie M, Jayyousi A . Role of SLMAP genetic variants in susceptibility of diabetes and diabetic retinopathy in Qatari population. J Transl Med. 2015; 13:61. PMC: 4335364. DOI: 10.1186/s12967-015-0411-6. View

. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):823-33. View

Merle N, Church S, Fremeaux-Bacchi V, Roumenina L . Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015; 6:262. PMC: 4451739. DOI: 10.3389/fimmu.2015.00262. View

Imesch P, Bindley C, Wallow I . Clinicopathologic correlation of intraretinal microvascular abnormalities. Retina. 1997; 17(4):321-9. DOI: 10.1097/00006982-199707000-00008. View

Klein B . Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007; 14(4):179-83. DOI: 10.1080/09286580701396720. View

Han J, Lando L, Skowronska-Krawczyk D, Chao D . Genetics of Diabetic Retinopathy. Curr Diab Rep. 2019; 19(9):67. PMC: 10292832. DOI: 10.1007/s11892-019-1186-6. View

Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E, Ksiazek A . TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron Physiol. 2007; 106(4):p69-75. DOI: 10.1159/000104874. View

10.

Chen C, Liou S, Wu H, Lin C, Huang L, Woung L . Regulatory SNPs Alter the Gene Expression of Diabetic Retinopathy Associated Secretary Factors. Int J Med Sci. 2016; 13(9):717-23. PMC: 5027191. DOI: 10.7150/ijms.16345. View

11.

Mohamed Q, Gillies M, Wong T . Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8):902-16. DOI: 10.1001/jama.298.8.902. View

12.

Stitt A, Curtis T, Chen M, Medina R, Mckay G, Jenkins A . The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2015; 51:156-86. DOI: 10.1016/j.preteyeres.2015.08.001. View

13.

Wang J, Yang M, Li Y, Liu G, Teng Y, Liu X . Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Mediators Inflamm. 2013; 2013:748435. PMC: 3707223. DOI: 10.1155/2013/748435. View

14.

Chen L, Zhang X, Wen F . Venous beading in two or more quadrants might not be a sensitive grading criterion for severe nonproliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2018; 256(6):1059-1065. PMC: 5956090. DOI: 10.1007/s00417-018-3971-3. View

15.

Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, Plana-Gil N, Soler-Lluis N, Mendez-Marin I . Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract. 2011; 94(1):126-32. DOI: 10.1016/j.diabres.2011.07.004. View

16.

Price L, Au S, Chong N . Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy. Clin Ophthalmol. 2015; 9:527-31. PMC: 4376301. DOI: 10.2147/OPTH.S79448. View

17.

Duh E, Sun J, Stitt A . Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight. 2017; 2(14). PMC: 5518557. DOI: 10.1172/jci.insight.93751. View

18.

Hampton B, Schwartz S, Brantley Jr M, Flynn Jr H . Update on genetics and diabetic retinopathy. Clin Ophthalmol. 2015; 9:2175-93. PMC: 4664538. DOI: 10.2147/OPTH.S94508. View

19.

Stitt A, ONeill C, ODoherty M, Archer D, Gardiner T, Medina R . Vascular stem cells and ischaemic retinopathies. Prog Retin Eye Res. 2011; 30(3):149-66. DOI: 10.1016/j.preteyeres.2011.02.001. View

20.

Moss S, Klein R, Klein B . The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998-1003. DOI: 10.1016/S0161-6420(98)96025-0. View